NBRV - Nabriva Therapeutics AG - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Nabriva Therapeutics AG's activity chart (see below) currently has 43 price targets and 33 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 59.21% with an average time for these price targets to be met of 440.21 days.

Most recent stock forecast was given by CARL BYRNES from NORTHLAND CAPITAL MARKETS on 06-Jan-2023. First documented stock forecast 13-Oct-2015.

Best performing analysts who are covering NBRV - Nabriva Therapeutics AG:

Adnan Butt Paul Matteis Kevin Kedra Ed Arce

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Jun-2020

$1

$0.6 (150.00%)

3 years 9 months 29 days ago
(06-Jan-2023)

1/4 (25%)

$-0.3 (-23.08%)

207

$500

$499.6 (124900.00%)

$500

5 years 10 months 28 days ago
(07-Dec-2020)

0/4 (0%)

$405.5 (429.10%)

Buy Since 08-Sep-2016

$2000

6 years 6 months 26 days ago
(09-Apr-2020)

1/6 (16.67%)

$1442.5 (258.74%)

291

Buy Since 20-Aug-2019

$250

$249.6 (62400.00%)

$1750

6 years 7 months 16 days ago
(19-Mar-2020)

1/3 (33.33%)

$107.5 (75.44%)

71

Hold Since 09-Jan-2020

$500

6 years 9 months 26 days ago
(09-Jan-2020)

2/2 (100%)

$-37.5 (-6.98%)

54

Show more analysts

Please expand the browser size to see the chart

What is NBRV (Nabriva Therapeutics AG) average time for price targets to be met?

On average it took 440 days for the stock forecasts to be reached, with an average price target met ratio of 59.21%.

Which analyst most recently updated their price target on NBRV (Nabriva Therapeutics AG)?

Carl Byrnes

Which analyst has the most public recommendations on NBRV (Nabriva Therapeutics AG)?

Carl Byrnes works at NORTHLAND CAPITAL MARKETS and has 8 price targets and 5 ratings on NBRV

Which analyst is the currently most bullish on NBRV (Nabriva Therapeutics AG)?

Paul Matteis with the highest potential upside of $5499.6

Which analyst is the currently most reserved on NBRV (Nabriva Therapeutics AG)?

Kevin Kedra with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?